Intravitreal dexamethasone (ozurdex) implant for radiation maculopathy secondary to stereotactic radiotherapy for posterior uveal melanoma

Conclusion: In our experience, intravitreal implantation of 0.7 mg dexamethasone is an anatomically, and to a lesser extent functionally effective procedure for radiation maculopathy after stereotactic radiotherapy for posterior uveal melanoma.
Source: Retinal Cases and Brief Reports - Category: Opthalmology Tags: Case Report Source Type: research